NCT00724425

A Phase 1 Dose Escalation Study of IPI-493

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of IPI-493 Orally Administered to Patients With Advanced Malignancies

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Infinity Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.

Detailed description

Hsp90 controls the proper folding, function, and stability of various "client" proteins within cells. Many of the clients of Hsp90 (such as Akt, Bcr-Abl, EGFR, Flt-3, c-Kit and PDGFR α) are oncoproteins or important cell-signaling proteins, and therefore are critical for tumor cell growth and survival. Inhibition of Hsp90 results in degradation of these proteins, which abrogates growth and survival signaling and leads to tumor cell death.

Conditions

• Advanced Malignancies

Interventions

Type	Name	Description
DRUG	IPI-493	Capsules, Multiple Schedules

Timeline

• Start date: 2008-07-01
• Primary completion: 2011-07-01
• Completion: 2011-07-01
• First posted: 2008-07-29
• Last updated: 2015-04-15

Locations

5 sites across 1 country: United States